• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate
Neohesperidin
Advantame
Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench
Pharma and Food Grade, USP/FCC Neotame Sweetener E961
Trilobatin

Samsung Bioepis gets nod for sale of biosimilar drug in Europe

firstwordpharmaMarch 06, 2019

Tag: Samsung Bioepis , NOD , biosimilar drug

  • Samsung Bioepis has won European approval of a 420-mg dosage of Ontruzant, a biosimilar of Roche's Herceptin, The Korea Herald reported Tuesday.

  • The drugmaker previously gained clearance for the 150-mg dosage in 2017.

  • "There is demand for both 150 mg and 420 mg products in Europe," a company official remarked, adding "we expect to provide more treatment opportunities for patients by expanding our product portfolio."

Register as Visitor to CPhI China 2019!

Previous:Johnson & Johnson's Spravato garners FDA approval for treatment-resistant depression

Next:Novo Nordisk Pharma Ltd. partners with Health2Sync in Japan, bringing digital diabetes management to healthcare providers and patients

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Samsung Bioepis gets nod for sale of biosimilar drug in Europe | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

Food ingredient Ganoderma applanatum Extract,Polysaccharides 45%

Food ingredient Ganoderma applanatum Extract,Polysaccharides 45%
3-Chloro-5-acetyliminodibenzyl

3-Chloro-5-acetyliminodibenzyl
N-(PHOSPHONOMETHYL)IMINODIACETIC ACID (PMIDA) (BY IDA & DEA ROUTES)

N-(PHOSPHONOMETHYL)IMINODIACETIC ACID (PMIDA) (BY IDA & DEA ROUTES)
4-Aminodiphenylamine sulfate (4698-29-7)

4-Aminodiphenylamine sulfate (4698-29-7)
square tube anodized

square tube anodized
Triterpene Reishi(Ganoderma lucidum) Mushroom Extract,Triterpene 10%

Triterpene Reishi(Ganoderma lucidum) Mushroom Extract,Triterpene 10%
Di-tert-butyl iminodicarboxylate

Di-tert-butyl iminodicarboxylate
Iminodiacetic acid

Iminodiacetic acid
chenodeoxycholic acid

chenodeoxycholic acid
Iminodibenzyl

Iminodibenzyl

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service